Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec:4:100089.
doi: 10.1016/j.lana.2021.100089. Epub 2021 Oct 1.

The regrettable story of the "Covid Kit" and the "Early Treatment of Covid-19" in Brazil

Affiliations
Review

The regrettable story of the "Covid Kit" and the "Early Treatment of Covid-19" in Brazil

Leonardo Furlan et al. Lancet Reg Health Am. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

LF has no interests to disclose. BC receives research support from Boehringer-Ingelheim, Amgen, consulting fees from Amgen, Bayer, honoraria for non-promotional speaking from Servier, Boehringer-Ingelheim, and from Elsevier's Order Sets.

Similar articles

Cited by

References

    1. Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390(10092):415–423. - PubMed
    1. Djulbegovic B, Guyatt G. Evidence-based medicine in times of crisis. J Clin Epidemiol. 2020;126:164–166. - PMC - PubMed
    1. DeJong C, Wachter RM. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19 – First, Do No Harm. JAMA Intern Med. 2020;180(8):1118. - PubMed
    1. Saag MS. Misguided Use of Hydroxychloroquine for COVID-19. JAMA. 2020;324(21):2161. - PubMed
    1. Ventura D, Reis R. An unprecedented attack on human rights in Brazil: the timeline of the federal government's strategy to spread Covid-19. Offprint. Translation by Luis Misiara, revision by Jameson Martins. Bulletin Rights in the Pandemic n. 10, São Paulo, Brazil, CEPEDISA/USP and Conectas Human Rights, January 2021.